Filing Details
- Accession Number:
- 0001140361-17-000832
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-01-05 18:52:01
- Reporting Period:
- 2017-01-04
- Filing Date:
- 2017-01-05
- Accepted Time:
- 2017-01-05 18:52:01
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1444380 | Nevro Corp | NVRO | Surgical & Medical Instruments & Apparatus (3841) | 562568057 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1622421 | Michael Enxing | C/O Nevro Corp. 1800 Bridge Parkway Redwood City CA 94065 | Vp Of Sales | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2017-01-04 | 1,500 | $3.60 | 41,963 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2017-01-04 | 600 | $74.96 | 41,363 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2017-01-04 | 500 | $76.12 | 40,863 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2017-01-04 | 400 | $76.97 | 40,463 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2017-01-04 | 1,500 | $0.00 | 1,500 | $3.60 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 78,608 | 2022-12-17 | No | 4 | M | Direct |
Footnotes
- Includes 2,500 restricted stock units.
- The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $74.59 to $75.26, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $75.59 to $76.57, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $76.87 to $77.04, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- 100% of the shares subject to the option are fully vested and exercisable.
Billionaire Hedge Funds
